Ranked by engagement

Top topics — all time page 19

Ranked by replies, likes and views over all time, with a bonus for topics that reached a marked solution. Engagement is a proxy for usefulness and a poor one; the documentation commons is the better index of what is settled.

This week This month This quarter This year All time

1,535 topics · page 19 of 40

Topic	Participants	Replies	Views	Activity
Where impurities in solid-phase peptide synthesis come from Analytics › Impurities & related substances water content data table HPLC endotoxin testing Solved Where impurities in solid-phase peptide synthesis come from Writing it up because I had to work it out twice and would rather nobody else did. A documentation question rather than an analytical one. I have a…	+54	59	14k	3mo
Second pass at: Retatrutide mass and identity: what a report should show Compounds › Retatrutide retatrutide randomised trial effect size Solved Second pass at: Retatrutide mass and identity: what a report should show — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 4 ( JAMA , 2021)…	+65	71	4.6k	13mo
Pancreatitis history and the risk calculus Safety › Contraindications delayed gastric emptying thyroid C-cell question pancreatitis pregnancy & planning Solved Posting this under the heading it deserves: Pancreatitis history and the risk calculus Everything below is what sits behind that. Asking about a population rather than about a person. The published trials in…	+28	32	52k	17h
What a regulator's shortage notice actually authorises — what changed since Sourcing › Regulatory research use only EMA FDA compounding Solved The question in the title: What a regulator's shortage notice actually authorises — what changed since I will give what I have already checked below so nobody repeats it. A logistics question, since the…	+22	26	53k	7mo
Journal club: SUSTAIN 6 and its retinopathy signal — does this still hold? Evidence › Journal club journal club effect size number needed to treat randomised trial The question in the title: Journal club: SUSTAIN 6 and its retinopathy signal — does this still hold? I will give what I have already checked below so nobody repeats it. I have seen SURMOUNT-2 ( Lancet ,…	+60	66	12k	16mo
[2026 update] Detection wavelength and why 214 nm and 280 nm disagree Analytics › HPLC & UHPLC HPLC system suitability gradient method Detection wavelength and why 214 nm and 280 nm disagree — setting out what I have, and where I think it stops being reliable. Posting the method first, because I know what the first three replies will…	+69	76	920	6h
The headache that turns out to be dehydration — the long version Nutrition & Training › Hydration & electrolytes blood pressure fatigue heart rate Under review On the subject in the title: The headache that turns out to be dehydration — the long version Working notes rather than a conclusion. Longitudinal report with the method stated, because a number without a…	+68	73	1.3k	12h
How compounding permissions changed when supply normalised Sourcing › Regulatory personal import EMA compounding research use only Solved Asking directly, because I could not find a straight answer: How compounding permissions changed when supply normalised Structured report rather than an opinion, following the format the maintainers asked…	+30	34	51k	16mo
Does dual agonism explain the effect size, or is it dose? Compounds › Tirzepatide SURPASS programme SURMOUNT programme tirzepatide randomised trial Solved Does dual agonism explain the effect size, or is it dose? I have a specific reason for asking rather than idle curiosity, and the context is below. Session topic: SURPASS-4 ( Lancet , 2021). Please read it…	+62	68	2.6k	29d
Deamidation and the close-eluting pair it produces Analytics › Impurities & related substances forced degradation HPLC water content data table Deamidation and the close-eluting pair it produces Writing it up because I had to work it out twice and would rather nobody else did. I would like to understand what this number means before I repeat it…	+33	37	46k	15mo
Coming back to: Nausea profile of amylin analogues compared with GLP-1 agonists Compounds › Cagrilintide & amylin analogues effect size cagrilintide cagrisema amylin analogues Posting this under the heading it deserves: Nausea profile of amylin analogues compared with GLP-1 agonists Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with FLOW ( N Engl…	+48	53	31k	13mo
Enforcement priorities versus written rules — does this still hold? Sourcing › Regulatory EMA MHRA compounding FDA Solved Under review Enforcement priorities versus written rules — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Structured report rather than an opinion, following…	+36	40	37k	11mo
US compounding rules and how they changed Regional › North America FDA telehealth insurance Closed US compounding rules and how they changed — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what determines the…	+62	68	1.4k	20mo
Preparing for an appointment: one page, three questions Clinical › Prescriber conversations prior authorisation type 2 diabetes telehealth Posting this under the heading it deserves: Preparing for an appointment: one page, three questions Everything below is what sits behind that. General question, not a request for advice about my own care — I…	+28	32	57k	11mo
Receptor desensitisation as a tolerance hypothesis, and its weak evidence Pharmacology › Receptor biology tirzepatide retatrutide amylin analogues long read Under review Receptor desensitisation as a tolerance hypothesis, and its weak evidence — setting out what I have, and where I think it stops being reliable. A documentation question rather than an analytical one. I have a…	+52	57	25k	just now
Angle of injection and whether 90 degrees is always right — the long version Practice › Administration injection site reaction needle gauge & length injection site rotation missed dose Pinned Angle of injection and whether 90 degrees is always right — the long version Writing it up because I had to work it out twice and would rather nobody else did. Reporting something rather than asking about it,…	+50	55	15k	2d
Blinding yourself: practical methods and their limits Research Methods › N-of-1 designs confounding data table effect size On the subject in the title: Blinding yourself: practical methods and their limits Working notes rather than a conclusion. Comparing PIONEER 6 ( N Engl J Med , 2019) with STEP 4 ( JAMA , 2021) and finding the…	+40	44	33k	5d
Coming back to: Why most self-reports here are not experiments, and that is fine Research Methods › N-of-1 designs worked example data table effect size Solved Closed The question in the title: Why most self-reports here are not experiments, and that is fine I will give what I have already checked below so nobody repeats it. Comparing LEADER ( N Engl J Med , 2016) with…	+56	62	11k	4mo
Manufacturer assistance programmes and their eligibility rules Access › Pricing formulary data table compounding On the subject in the title: Manufacturer assistance programmes and their eligibility rules Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category…	+37	42	32k	11d
How shortages have affected compounding permissions Access › Shortages shortage compounding FDA formulary How shortages have affected compounding permissions I have a specific reason for asking rather than idle curiosity, and the context is below. A coverage question with the paperwork detail included, since that…	+61	71	3.6k	2d
Irish differences from the UK position Regional › UK & Ireland MHRA cost per milligram NHS Solved Posting this under the heading it deserves: Irish differences from the UK position Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this category expires.…	+62	66	993	21mo
Aggregate verification data across the directory, with caveats Sourcing › Independent verification Medutest blind sampling PeptideMeter Under review On the subject in the title: Aggregate verification data across the directory, with caveats Working notes rather than a conclusion. Structured report rather than an opinion, following the format the…	+64	74	4.6k	14h
A rising related-substance total over six months: degradation or method drift? Analytics › Impurities & related substances data table endotoxin testing HPLC Closed Asking directly, because I could not find a straight answer: A rising related-substance total over six months: degradation or method drift? Posting the method first, because I know what the first three…	+37	42	37k	23mo
Follow-up: Reading an interaction checker output critically Practice › Interactions insulin hypoglycaemia delayed gastric emptying needs a source Solved Reading an interaction checker output critically — setting out what I have, and where I think it stops being reliable. I have read the maintained page on this and I still have a gap, so I am asking rather…	+62	66	13k	2d
Coming back to: Renal impairment: what the labelling says about dose Clinical › Special populations chronic kidney disease adolescents disordered eating pregnancy & planning Renal impairment: what the labelling says about dose — setting out what I have, and where I think it stops being reliable. Asking about a population rather than about a person. The published trials in this…	+30	34	48k	18mo
Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset Evidence › Journal club randomised trial risk of bias effect size estimand Posting this under the heading it deserves: Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022) with FLOW…	+58	64	17k	13mo
Reused chromatograms across lots: how to spot it Analytics › COA interpretation batch & lot numbers amino acid analysis documentation quality certificate of analysis On the subject in the title: Reused chromatograms across lots: how to spot it Working notes rather than a conclusion. A documentation question rather than an analytical one. I have a certificate in front of…	+53	60	9.5k	4h
Splitting a weekly dose in two: the pharmacokinetic argument against Practice › Dosing & titration titration tirzepatide semaglutide missed dose Splitting a weekly dose in two: the pharmacokinetic argument against — setting out what I have, and where I think it stops being reliable. I have read the maintained page on this and I still have a gap, so I…	+24	28	51k	5mo
Why the Start Here categories exist, and what they are not for Start Here › Welcome guidelines trust levels onboarding beginner friendly Solved Why the Start Here categories exist, and what they are not for — that is the question, and I have not found it answered plainly anywhere I have looked. Question in the title. Context below, and I have tried…	+40	44	32k	1d
Chain of custody for a sample you posted yourself — one year on Sourcing › Independent verification VendorInvestigate Janoshik Analytical blind sampling third-party testing Posting this under the heading it deserves: Chain of custody for a sample you posted yourself — one year on Everything below is what sits behind that. Structured report rather than an opinion, following the…	+28	32	50k	15h